Skip to main content
Fresenius Kabi is expanding its Melrose Park, Illinois site to significantly increase capacity for the production of injectable generic pharmaceuticals. The multi-stage expansion at the facility, just outside of Chicago, will include construction of a number of new buildings. Completion is scheduled for 2026, following an investment of nearly $250 million. www.fresenius-kabi.us